viewCann Group Ltd

Cann Group has funding options on the table for medical cannabis

The halt will remain in place until Monday 4th December 2017.

The company's shares are in pre-open

Cann Group Ltd (ASX:CAN) has been one of the leading medical cannabis focused stocks on the ASX over the past year, making a near 400% gain to $3.00.

Cann is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia.

Recently the company was granted a licence to import and/or export cannabis genetics and medicinal cannabis products by the Australian Government Department of Health, through the Office of Drug Control (ODC).

As a holder of this licence, the Company can now apply for a permit to export raw cannabis material and cannabis oil for analytical testing.

To continue the next steps, Cann is heading to market with a capital raising in the form of a placement to institutional, sophisticated and other professional investors.

A share purchase plan will also be offered.

The halt will remain in place until the opening of trade on Monday 4th December 2017, or earlier if an announcement is made to the market.

Quick facts: Cann Group Ltd

Price: 0.575 AUD

Market: ASX
Market Cap: $155.24 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


First Cobalt Corp takes step forward the Cobalt Camp with the start of...

First Cobalt Corp (CVE: FCC- OTCQX: FTSSF) Vice President of Exploration Frank Santaguida joined Steve Darling from Proactive to shares news the company is getting to work starting a geophysical survey to follow up on high-grade silver and cobalt intercepts in a historic mining area of the...

13 hours, 44 minutes ago

2 min read